Skip to content

Effect of electrical stimulation on muscle and its result on inflammation, muscle mass and function in cancer patients

Effect of neuromuscular electric stimulation on inflammation, mass and muscular function in patients with cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7z5c63
Enrollment
Unknown
Registered
2020-09-23
Start date
2018-12-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Interventions

A group of 28 patients will be recruited and randomized into 2 groups. Control Group (CG): Composed of 14 individuals (n = 14) who will pass a staging of the passage of electrical stimuli, placing the
and a pulse width of 250 ms and the stimulation phase, which will be carried out in 30 minutes, with a frequency of 100 Hz
with pulse width of 400 ms
stimulus regime: 5 s on / 10 s off). The neuromuscular stimulus will be performed twice a day, with an interval of 3 h between sessions on seven consecutive days. The process will be done in such a wa
Device
E02.331.800

Sponsors

Tatyanne Letícia
Lead Sponsor
Faculdade de Nutrição da Universidade Federal de Goiás
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Cancer patients; both sexes; age over 18 years; admitted to a hospital during the study period.

Exclusion criteria

Exclusion criteria: Serious heart disease; exclusive palliative care; the presence of metallic implants in the region where the electrical stimulus is applied; practice of physical activity in the last six months; amputees; presence of epidermal lesion in the lower limbs; cognitive impairment and expected discharge from hospital less than 14 days.

Design outcomes

Primary

MeasureTime frame
It is expected to find that patients in the intervention group receiving neuromuscular electrostimulation associated with a high-protein diet have at least 3% less muscle loss in the quadriceps region compared to the control group.

Secondary

MeasureTime frame
It is expected to find in the cancer patients evaluated before the intervention a prevalence of sarcopenia of at least 30%.

Countries

Brazil

Contacts

Public ContactTatyanne Gomes

Faculdade de Nutrição da Universidade Federal de Goiás

tatyanneleticianogueiragomes@gmail.com+55-62-996748632

Outcome results

None listed

Source: REBEC (via WHO ICTRP)